<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4149680_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152625</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>5</safetyreportversion>
		<safetyreportid>PHHY2012IT079620</safetyreportid>
		<primarysourcecountry>IT</primarysourcecountry>
		<occurcountry>IT</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130125</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20120911</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130121</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012IT079620</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<linkedreport>
			<linkreportnumb>175292</linkreportnumb>
		</linkedreport>
		<linkedreport>
			<linkreportnumb>175288</linkreportnumb>
		</linkedreport>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>IT</reportercountry>
			<qualification>3</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>IT</reportercountry>
			<qualification>3</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>IT</reportercountry>
			<qualification>1</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientagegroup>5</patientagegroup>
			<patientsex>2</patientsex>
			<reaction>
				<primarysourcereaction>Loss of consciousness</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Loss of consciousness</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Loss of consciousness</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120323</reactionstartdate>
				<reactionfirsttime>61</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Clinical lack of efficacy</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Lack of drug effect</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Drug ineffective</reactionmeddrapt>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>GILENYA</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugbatchnumb>S0023</drugbatchnumb>
				<drugauthorizationnumb>22-527</drugauthorizationnumb>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>.5</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>0.5 mg, daily</drugdosagetext>
				<drugdosageform>Capsule</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Multiple sclerosis</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20120123</drugstartdate>
				<drugstartperiod>61</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20121120</drugenddate>
				<drugtreatmentduration>303</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>1</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>FINGOLIMOD</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Loss of consciousness</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Loss of consciousness</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>CIPRALEX</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugstructuredosagenumb>10</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>10 mg, UNK</drugdosagetext>
				<drugdosageform>Coated tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Multiple sclerosis</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20100330</drugstartdate>
				<drugstartperiod>725</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>ESCITALOPRAM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>TOPAMAX</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugstructuredosagenumb>50</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>50 mg, UNK</drugdosagetext>
				<drugdosageform>Coated tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Multiple sclerosis</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20090825</drugstartdate>
				<drugstartperiod>942</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>TOPIRAMATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>LYRICA</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugstructuredosagenumb>75</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>75 mg, UNK</drugdosagetext>
				<drugdosageform>Capsule</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20120625</drugstartdate>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>PREGABALIN</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012IT079620, is a combined initial spontaneous report received from a healthcare professional (HCP) on 11 Sep 2012 and forwarded by health authority (HA) (HA's number: 175292) on 13 Sep 2012 and follow up report received from a healthcare professional on 11 Sep 2012 and forwarded by health authority (HA) (HA's number: 175288) on 14 Sep 2012 and follow up report received from a healthcare professional on 21 Nov 2012 and follow up report received from a healthcare professional and forwarded by health authority (HA) (HA's number: 175288) on 14 Dec 2012 and follow up received from a quality assurance (QA) department on 21 Jan 2013: This is also a quality complaint (AQWA: 637893). This report refers to a 32-year-old female patient. The patient's medical history was not reported. The patient's concomitant medications included Cipralex (escitalopram), Topamax (topiramate) and Lyrica (pregabalin). This patient had been treated with Gilenya (fingolimod) 0.5 mg (batch no: S0023) for multiple sclerosis from 23 Jan 2012. The patient experienced loss of consciousness on 23 Mar 2012 and 17 Aug 2012. After the episode of 17 Aug 2012 (episode IV), the patient didn&#8217;t perform tests, but the episode resolved spontaneously without administration of medications and the patient continued to take Gilenya. On 20 Nov 2012, the patient suspended Gilenya due to clinical lack of efficacy. The HCP assessed the relationship between the event loss of consciousness and Gilenya as possible and causality for the event clinical lack of efficacy was not reported. Batch number was sent to local QA for investigations. No more information was available.

Follow up report received from a healthcare professional on 11 Sep 2012 and forwarded by health authority (HA) (HA's number: 175288) on 14 Sep 2012: Information related to the concomitant medication (Lyrica), therapy dates of the existing concomitant medications and event occurrence was updated.

Follow up report received from a healthcare professional on 21 Nov 2012: Information related to the patient (patient didn&#8217;t perform tests, the episode resolved spontaneously without administration of medications and the patient continued to take Gilenya), addition of new event (clinical lack of efficacy) and action taken with Gilenya (discontinued on 20 Nov 2012) were up dated.

Follow up report received from a healthcare professional and forwarded by health authority (HA) (HA's number: 175288) on 14 Dec 2012: Batch number of Gilenya (S0023) updated. Batch number was sent to local QA for investigations.

Follow up received from a quality assurance department on 21 Jan 2013: This is also a quality complaint (AQWA: 637893).</narrativeincludeclinical>
				<sendercomment>Medic Comment: The available reported data does not allow for a proper causality assessment. The case has been conservatively assessed as suspected and will be reassessed after the availability of follow up</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
